Cargando…
Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
We present the case of an old woman with ALK-rearranged stage IV lung adenocarcinoma who received crizotinib. She presented with severe dyspnea on the 34th day, and diffuse ground-glass opacifications in her chest. A diagnosis of crizotinib-induced ILD was confirmed. Corticosteroids were administere...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863787/ https://www.ncbi.nlm.nih.gov/pubmed/31250326 http://dx.doi.org/10.1007/s10456-019-09673-1 |
_version_ | 1783471761708285952 |
---|---|
author | Xie, Xiaohong Guo, Bingpeng Lin, Xinqing Qin, Yinyin Ouyang, Ming Li, Shiyue Zhou, Chengzhi |
author_facet | Xie, Xiaohong Guo, Bingpeng Lin, Xinqing Qin, Yinyin Ouyang, Ming Li, Shiyue Zhou, Chengzhi |
author_sort | Xie, Xiaohong |
collection | PubMed |
description | We present the case of an old woman with ALK-rearranged stage IV lung adenocarcinoma who received crizotinib. She presented with severe dyspnea on the 34th day, and diffuse ground-glass opacifications in her chest. A diagnosis of crizotinib-induced ILD was confirmed. Corticosteroids were administered. However, the disease was still progressing rapidly. Therefore, as a monoclonal antibody against vascular endothelial growth factor, bevacizumab was administered in low doses (200 mg on days one and three). Her symptoms began to improve. Our clinical experience indicates that bevacizumab combined with corticosteroids might be a promising treatment in crizotinib-induced ILD patients. |
format | Online Article Text |
id | pubmed-6863787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-68637872019-12-03 Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease Xie, Xiaohong Guo, Bingpeng Lin, Xinqing Qin, Yinyin Ouyang, Ming Li, Shiyue Zhou, Chengzhi Angiogenesis Perspective We present the case of an old woman with ALK-rearranged stage IV lung adenocarcinoma who received crizotinib. She presented with severe dyspnea on the 34th day, and diffuse ground-glass opacifications in her chest. A diagnosis of crizotinib-induced ILD was confirmed. Corticosteroids were administered. However, the disease was still progressing rapidly. Therefore, as a monoclonal antibody against vascular endothelial growth factor, bevacizumab was administered in low doses (200 mg on days one and three). Her symptoms began to improve. Our clinical experience indicates that bevacizumab combined with corticosteroids might be a promising treatment in crizotinib-induced ILD patients. Springer Netherlands 2019-06-27 2019 /pmc/articles/PMC6863787/ /pubmed/31250326 http://dx.doi.org/10.1007/s10456-019-09673-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Perspective Xie, Xiaohong Guo, Bingpeng Lin, Xinqing Qin, Yinyin Ouyang, Ming Li, Shiyue Zhou, Chengzhi Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title | Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title_full | Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title_fullStr | Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title_full_unstemmed | Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title_short | Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
title_sort | successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863787/ https://www.ncbi.nlm.nih.gov/pubmed/31250326 http://dx.doi.org/10.1007/s10456-019-09673-1 |
work_keys_str_mv | AT xiexiaohong successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT guobingpeng successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT linxinqing successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT qinyinyin successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT ouyangming successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT lishiyue successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease AT zhouchengzhi successfultherapywithbevacizumabcombinedwithcorticosteroidsforcrizotinibinducedinterstitiallungdisease |